`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`WATSON LABORATORIES, INC.
`Petitioner
`
`V.
`
`UNITED THERAPEUTICS, INC.
`
`
`Patent Owner
`
`Patent No. 9,358,240
`
`Issue Date: June 7, 2016
`
`Title: TREPROSTINIL ADMINJSTRA TION BY INHALATION
`
`
`
`Inter Partes Review No. 2017-01621
`
`
`
`DECLARATION OF DR. FRANK REICBENBERGER
`
`4818-5875-5150
`
`UNITED THERAPEUTICS, EX. 2027
`
`
`WATSON LABORATORIES V. UNITED THERAPEUTICS. IPR2017-01621
`Page 1 of 5
`
`
`
`IPR2021-00406
`United Therapeutics EX2068
`
`
`
`IPR2017-0162!
`
`Declaration of Dr. Frank Reichenberger
`
`I, Dr. Frank Reichenberger, hereby declare as follows:
`
`1.
`
`I was a memberof University of Giessen and Marburg Lung Center
`
`(“UGMLC”), a research centerat the University Hospital Giessen studying
`
`pulmonary hypertension.
`
`2.
`
`Lam nota paid consultant for United Therapeutics Corporation, which
`
`I understand is the assignee of U.S. Patent No. 9,358,240, in connection with
`
`JTPR2017-01621.
`
`3.
`
`I am aco-author of the German language article: Hossein Ardeschir
`
`Ghofrani ef ai. “Neue Therapieoptionen in der Behandlung der pulmonalarteriellen
`
`Hypertonie,”’ Herz, 30, 4 (June 2005): 296-302 (“the Ghofraniarticle”). I
`
`understand that Watson Laboratories, Inc. (“Watson”) submitted an English
`
`languagetranslation ofthis article in this proceeding (Exhibit 1005), which I have
`
`reviewed.
`
`4,
`
`Dr. Friedrich Grimminger and I both have experience in the use of
`
`selective endothelin A receptor agonists for treatment pulmonary hypertension.
`
`Therefore, we were asked by Dr. Werner Seegerto draft the section of the
`
`Ghofraniarticle relating to selective endothelin A receptor agonists. And indeed,
`
`wedid draft this section. In Exhibit 1005,this section is on page 3. In line with
`
`' Thetitle is translated as “Newtherapiesin the treatmentofpulmonary
`
`hypertension” in Exhibit 1005.
`
`4618-5875-5150
`
`
`
`IPR2017-01621
`
`Declaration ofDr. Frank Reichenberger
`
`the normalpractice in the UGMLCresearch center, both Dr. Grimminger and I
`
`were listed as authors on the Ghofrani article for this contribution.
`
`5.
`
`I did not make material contributionsto any other section of the
`
`Ghofrani article, and J specifically did not contribute to the following excerpt:
`
`Initial trials in Giessen have shown proofofefficacy of inhaled
`treprostinil for the effective reduction of the pulmonaryvascular
`resistance (PVR)[6]. In this first study, 17 patients with severe pre-
`capillary pulmonary hypertension were administered inhaled
`treprostinil (15 meg/inhalation). This led to a major reduction in
`pulmonary selective pressure and resistance with an overall duration
`of action of > 180 min. In direct comparison with inhaled iloprost,
`
`inhaled treprostinil showed a stronger pulmonary selectivity, so that it
`
`is possible to increase the dosage to up to 90 mcg (absolute inhaled
`
`dose per inhalation exercise) without adverse effects occurring [6].
`
`Dueto these unique properties (pronounced pulmonary selectivity and
`
`long duration of action after an individual inhalation), it is possible to
`
`reduce the number inhalations necessary to up to four per day; the
`
`inhalation period can be reduced to < 1 min. by selecting a suitable
`
`device, Additionally, the initial data showsthatit is technically
`
`feasible for there to be only one to two breaths in an application.
`
`The information in this excerpt was compiled and composed by Dr. Robert
`
`Voswinckel and Dr. Werner Seeger, and the idea to perform the underlying work
`
`originated with them.
`
`4818-5875-5150
`
`
`
`IPR2017-01621
`
`Declaration of Dr. Frank Reichenberger
`
`6. Dr. Hossein A. Ghofrani — thefirst listed author drafted the section of the
`
`Ghofrani article relating to phosphodiesterase inhibitors, and the remaining
`
`sections on vasoactive therapy,inhaled iloprost, combination therapies, and
`
`treatment of early forms of treatment of pulmonary hypertension, as well as the
`
`introduction were drafted by Dr. Hossein A. Ghofrani and Dr. Werner Seeger.
`
`[The remainderofthis pageis intentionally left blank]
`
`4818-5875-5150
`
`
`
`IPR2017-01621
`
`Declaration of Dr. Frank Reichenberger
`
`7. Ihereby declare thatall statements made herein of my knowledgearetrue
`
`andthat all statements made on information and belief are believed to be true; and
`
`further that these statements were made with the knowledgethat willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both
`
`under Section 1001 of Title 18 of the United States Code.
`
`Date: AHA f___,2017
`
`ary »
`
`
` Dr. Frank Reichenbe:
`
`4818-5875-5150
`
`